

## Programme & speakers

---

### Day 1 - Tuesday 27th June 2017

---

08.45 Registration & welcome coffee  
09.15 - 09.30 Welcome Address

### 09.30 - 11.00 Keynote Session I: ADCs, Empowering Cancer Therapy

---

Chairperson: **Nicolas Joubert, Université de Tours**



Antibody-Drug Conjugates for Cancer: Current Progress and Future Prospects.

**Ravi Chari, Ph.D.** - Vice President, Chemistry & Biochemistry, Distinguished Research fellow - **Immunogen**



Advancement in Antibody Drug Conjugates: A Step Closer to Magic Bullets in War against Cancer

- Advancement in ADCs unleashing a strong clinical pipeline of very promising anticancer drugs
- Five Rights of ADCs, meeting the challenges of off-target toxicities
- Translational approaches to ADC development

**Rakesh Dixit, Ph.D., DABT** - Vice President R & D, Global Head, Biologics Safety Assessment - **MedImmune Inc.**

### 11.00 - 11.30 Coffee Break and Poster Session - Partnering (B2B meetings)

---

### 11.30 - 12.15 Session II - part 1: Discovery of Novel ADCs Targets and Formats

---

Chairperson: **Maxime Lampilas, Sanofi**




Anthracycline-based ADCs :  
Anthracycline-based antibody drug conjugates with potent immune-stimulatory functions

**Roger Beerli, Ph.D.** - Chief Scientific Officer - **NBE Therapeutics**



*Sponsored presentation*

Tissue Screen : the tissue based approach to target relevant protein

**Renaud Burrer** - R&D Manager - 

### 12.15 - 13.30 Lunch and Poster Session - Partnering (B2B meetings)

---

### 13.30 - 15.00 Session II - part 2: Discovery of Novel ADCs Targets and Formats

---



An auristatin-based anti-HER3 ADC enhances the efficacy of radiation therapy in pancreatic cancer

**Thierry Chardès, Pharm. D., Ph.D.** - CNRS Research Director - **Research Institute of Cancerology in Montpellier - LabEx MabImprove**



Small is Beautiful - Humabody® Drug Conjugates, HDCs a Real Alternative to ADCs

**Thomas Sandal** - Vice President R&D - **Crescendo Biologics**



The two faces of interleukin-2; engineering towards applications in oncology and autoimmune diseases  
**Ekkehard Moessner, Ph.D.** - Head of Protein Engineering - **Roche Innovation Center, Large Molecules Research**

## 15.00 - 15.30 Coffee Break and Poster Session - Partnering (B2B meetings)

---

## 15.30 - 18.30 Pitch Session - New ADC Formats: Diagnostic and Immunomonitoring

---

Chairpersons: **Andreas Pahl, Heidelberg Pharma** - **Saïd El Alaoui, Covalab**

**Pitch # 1 :**

**Gokhan YAHIOGLU - Antikor Biopharma**

Not too big - Not too small : Fragment Drug Conjugates (FDCs) as alternatives to ADCs for solid tumors

**Pitch # 2 :**

**Mathieu CINIER - Affilogic**

Nanofitins as a versatile platform for cancer imaging and drug conjugates

**Pitch # 3 :**

**Bruno TILLIER - Synthelis**

Cell-free expression as an innovative tool for antigen production

**Pitch # 4 :**

**Jonathan SJÖGREN - Genovis**

The novel site specific ADC technology GlyCLICK preserves immunoreactivity and allows quantitative conjugation of functional groups to antibody Fc-glycans

**Pitch # 5 :**

**David BONNAFOUS - McSAF**

New linker technologies of ADC & bioconjugates developments

**Pitch # 6 :**

**Jean VIALLET - Inovotion**

INOVOTION Tests for drug discovery: Early identification of low value ADC

**Pitch # 7 :**

**Thibault JONCKHEERE - ImmunXperts**

Early Immunogenicity and Immunotoxicity Assessment and Risk Management for ADCs

**Pitch # 8 :**

**Oreda BOUSSADIA - Epivax**

The ISPRI Toolkit Rapidly Screens ADC Candidates for Immunogenic Potential Driven by T cell Epitope Content and Foreignness

**Pitch # 9 :**

**Serge DESMOULINS - Agilent**

Drug-to-antibody ratio determination for ADCs in serum enabled by a sample preparation platform that automates affinity purification and deglycosylation

**Pitch # 10 :**

**Lisa RECNİK - ICRM-IBMM**

Development of an Antibody Radiolabeled Drug Conjugate (ARDC) using 195mPt-Carboplatin for Theranostic Approach in Ovarian Cancer

**Pitch # 11 :**

**Jean-Marc JOUMIER - EasyChelators**

C-functionalized Cyclam derivatives as bifunctional chelating agent (BCA) analogues of TETA, TE2A and CB-TE2A

18.30 End of Day 1

20.00 Gala Dinner

## Day 2 - Wednesday 28th June 2017

---

08.15 Registration & welcome coffee

## 08.30 - 10.30 Session III - Accelerate the Development of the Next-Generation ADCs

---

Chairperson: **Alain Beck, Centre d'Immunologie Pierre Fabre**



CovIsoLink™: New bacterial transglutaminase Q-tag substrate for the development of site specific Antibody Drug Conjugates

**Saïd El Alaoui, Ph.D.** - Chief Executive Officer - **Covalab**



Enzymatic site specific conjugation using transglutaminase to obtain homogeneous ADC

**François Romagné, Ph.D.** - Scientific Director - **MI-mAbs**



Amanitin-based Antibody-Drug-Conjugates as New Therapeutic Modalities for Cancer Therapy

**Andreas Pahl, Prof. Dr.** - Chief Scientific Officer - **Heidelberg Pharma**



Development of new cryptophycins as promising tubulin binder payloads for ADCs

**Marie-Priscille Brun, Ph.D.** - Immunoconjugate Leader / Chemical biology group - **Sanofi**

**10.30 - 11.00 Coffee Break and Poster Session - Partnering (B2B meetings)**

---

**11.00 - 12.30 Session IV - Challenges in ADC developability, scale-up and manufacturing**

---

Chairperson: **François Romagné, MI-mAbs**



**Keynote presentation**

Insights of multilevel state-of-the art analytical methods for ADCs structural assessment

**Alain Beck, PhD** - Senior Director, Analytical Chemistry, New Biological Entities - **Centre d'Immunologie Pierre Fabre** - Associate Editor of **mAbs journal**



*Sponsored presentation*

ADC Easy Access : From the Lab to the Clinic

**Régis Lelou** - Senior Bioengineer - R&D Chemicals



*Sponsored presentation*

**Integrated services for immuno-conjugate development and production:**

Symbiotic combination of R&D expertise and industrial leadership for successful development of mAbs

**Eric Devic, Ph. D.** - Founder-President and COO - **GTP Technology**



Novasep's integrated solutions for ADC

**François D'Hooge, Ph.D.** - Head of Bioconjugation Unit - **Novasep**



Need for speed - how to accelerate the development of an ADC

**Klaus Kaiser** - Head of Downstream - **Bayer**

**12.30 - 14.00 Lunch and Poster Session - Partnering (B2B meetings)**

---

**14.00 - 16.00 Session V - Moving ADCs Forward Into the Clinic: Safety and Efficacy**

---

Chairperson: **François Lefoulon, Servier**



Update on PBDs

**Philip Howard, Ph.D.** - CSO, Senior Fellow - **Spirogen**



Mechanisms of resistance to ADCs

**Charles Dumontet, Prof. Ph.D** - Senior Physician in Hematology - **Hospices civils de Lyon**



Clinical pharmacology of ADCs

**Gilles Paintaud, PU-PH** - Head of CNRS UMR 7292 - **University of Tours** - **LabEx MabImprove**





ADC Safety & Toxicity: Technology Choices and Importance of Process Development to Control Safety related CQAs  
**Olivier Marcq, Ph.D.** - Group leader Development and Manufacturing - **Agensys**

**16.00 - 17.00 Outsourcing roundtable: mAbs and ADCs outsourcing, opportunities and challenges - Partnering (B2B meetings)**

---

Chairperson: **Florence Lhospice**, Innate Pharma

**Arnaud Martin**, Director CMO Business - **Sanofi**

**Régis Lelou**, Senior Bioengineer - R&D Chemicals - **Lonza**

**Christophe Aussourd**, Planning and Supply Director - **Servier**

**17.00 - 17.30 Closing Remarks, Announcement of the AIS2018**

---

17.30 End of Symposium